The New York Post said weight-loss drugs like Vegovy (marketed as Ozempic to treat diabetes) have become Hollywood’s biggest weight-loss secret, and an even more powerful pound-buster may soon be on the market. .
Tirazeptide, which is injected weekly into the arm, thigh or abdomen, is likely to be approved by the Food and Drug Administration for weight loss in 2023.
Manufactured by Eli Lilly, the drug is already approved by the FDA for the treatment of diabetes under the name Monjaro. However, taken in high doses, it has been shown to aid weight loss by reducing appetite and food intake, as well as simplifying the way the body breaks down sugar.
In a clinical trial, participants lost up to 22.5% of their body weight, or about 52 pounds (23.5868 kg), over the course of 72 weeks when they took the high dose of tirgepatide. Unlike the popular weight loss drugs Wegovy and Saxenda, tirezepatide mimics not one but two appetite-regulating hormones (GLP1 and GIP), which appears to make it more effective.
There is concern in the United States that the drug used to treat obesity is not covered by insurance. Such is the case with Wegovy, which costs about $1,300 for a month’s supply. The low doses used to treat diabetes are usually covered by insurance.
Dr. David Rindt, medical director of the Institute for Clinical and Economic Review, told the Post that tirgepatide could cost as much as $13,000 a year, or about $1,100 a month. too expensive? Well, people copy celebrities.
Elon Musk admitted to using Vegovy to lose 20 pounds, and social media users speculated about Kim Kardashian’s use of these drugs, and TV host Andy Cohen tweeted last year: “Everyone suddenly gained 25 pounds.” What happens when they stop taking Ozempic?
In fact, Ozempic and Vigovi are currently listed on the FDA site as “currently deficient.” But all “miracle” drugs have their consequences, with the most common side effects of tirazeptide documented so far being nausea, constipation, and diarrhea.